SCHEMBL362584

SCHEMBL362584

CCOC(=O)C(C#N)=C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
MAPT P10636 5/20 0.54
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 8/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 3/20 0.49
TSHR P16473 2/20 0.46
LMNA P02545 2/20 0.44
MAPK1 P28482 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
RAB9A P51151 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14626678 1.00 MEN1 (0.56) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL13310876 1.00 MEN1 (0.56) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL3634417 0.98 MEN1 (0.57) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL625332 0.95 MEN1 (0.57) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL20825386 0.89 MEN1 (0.47) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL25057561 0.85 KMT2A (0.54) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL8198931 0.85 MAPT (0.50) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL8202715 0.85 KMT2A (0.49) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL5370952 0.83 KMT2A (0.53) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL15577187 0.83 MAPT (0.55) MEN1KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-12-23 US disclosed
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-12-26 US disclosed
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University-Of The Commonwealth System Higher Education (US) 2024-02-13 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
EP-3738955-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University Of The Commonwealth System Of Higher Education (US) 2020-11-18 EP disclosed
US-7511157-B2 racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-31 US disclosed
WO-2007094885-A2 IDENTIFICATION OF A NITRILASE FROM B. JAPONICUM BY RATIONAL GENOME MINING AND METHODS OF USE SOUTHERN METHODIST UNIVERSITY (US) 2007-08-23 WO disclosed
US-20070178575-A1 Identification Of A Nitrilase From B. Japonicum By Rational Genome Mining And Methods Of Use SOUTHERN METHODIST UNIVERSITY 2007-08-02 US disclosed
US-20070178575-A1 Identification Of A Nitrilase From B. Japonicum By Rational Genome Mining And Methods Of Use SOUTHERN METHODIST UNIVERSITY 2007-08-02 US disclosed
US-7030267-B2 Cycloproply β-amino acid derivatives WARNER-LAMBERT COMPANY, LLC (US) 2006-04-18 US disclosed
WO-2006007700-A1 HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-26 WO disclosed
EP-1592661-A2 CYCLOPROPYL BETA-AMINO ACID DERIVATIVES Warner-Lambert Company LLC (US) 2005-11-09 EP disclosed
WO-2004065361-A2 CYCLOPROPYL BETA-AMINO ACID DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2004-08-05 WO disclosed
US-20040147608-A1 Cyclopropyl beta-amino acid derivatives SCHWARZ JACOB BRADLEY (US) 2004-07-29 US disclosed
US-4261988-A ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY BAYER AKTIENGESELLSCHAFT (DE) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 MEN1 3312/4885KMT2A 3078/4885MAPT 1051/4885
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 MEN1 4844/4885KMT2A 2208/4885MAPT 878/4885
US-20040147608-A1 Cyclopropyl beta-amino acid derivatives CACNA1S, CACNA1D, CACNA1B MEN1 2869/4885KMT2A 2516/4885MAPT 1074/4885
US-11028052-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 MEN1 649/4885KMT2A 2891/4885MAPT 1245/4885
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 MEN1 3312/4885KMT2A 3078/4885MAPT 1051/4885
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A MEN1 3699/4885KMT2A 3665/4885MAPT 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.